By linking FAM20C kinase to adipocyte inflammation, adipose insulin resistance, and systemic metabolic impairment, we expand the current understanding of molecular pathways that transition obesity into T2D, highlighting adipocyte FAM20C as a potential therapeutic target. This evidence concerns the gene FAM20C and type 2 diabetes mellitus.